Retina Global is governed by the Board of Directors.
The current board members are:
- Mike T Trese, MD, USA
- Suber S Huang, MD MBA, USA
- Francesco Bandello, MD, Italy
- Alan C Bird, MD, UK
- Jose-Alain Sahel, MD, France
- Susan Orr, OD, USA
- Adrienne L Graves, PhD, USA
- Ram Palanki, PharmD, USA
- Pravin Dugel, MD, USA
- Tien Yin Wong, MD PhD, Singapore
- Dimitri Azar, MD MDA, USA
- Rajat N Agrawal, MD MS, CEO, USA
Dr. Trese received his undergraduate degree from the University of Michigan, his O.D. from Pennsylvania College of Optometry, and earned his M.D. degree from Georgetown University, School of Medicine. Dr. Trese served as Director of Vitreoretinal Surgery at the University of Kansas prior to joining Associated Retinal Consultants in 1982. He currently is Clinical Professor of Biomedical Sciences at The Eye Research Institute of Oakland University, Clinical Associate Professor at Wayne State University School of Medicine, and Chief of Pediatric and Adult Vitreoretinal Surgery at William Beaumont Hospital.
Dr. Trese is an internationally recognized expert in retinopathy of prematurity and pediatric retinal disease. His current basic science and clinical research interests encompass both pediatric and adult retinal disorders, including participation in National Institute of Health and National Eye Institute sponsored trials. He has spoken all around the world, delivered several named lectureships, and has authored numerous publications and textbook chapters.
Dr. Huang is currently the CEO of the Retina Center of Ohio and Voluntary Assistant Clinical Professor of Ophthalmology at Bascom Palmer Eye Institute, University of Miami. Dr. Huang is Chair, NEI/NIH National Eye Health Education Program and is the AAO representative to the United States Pharmacopeia (USP). He is the former AAO Associate Secretariat of Federal Affairs; Chair, Research, Regulatory, and External Scientific Affairs Committee; and Chair, Compounding Pharmacy taskforce, and is the current AAO representative to the USP. Past President of the American Society of Retina Specialists, he founded the Retina Image Bank, which has become the world’s largest and most comprehensive open-access multimedia database of “all things retina”. He is an editor for the APJO and APAO Chair, Retina Vitreous on-line education. He is a bioscience advisor to the Anderson Scholars program and Life Trustee at the University School. He is editor-in-chief of the ASRS Retina Atlas with expected completion in 2020. He is also President/CEO of The Future Vision Foundation, whose mission celebrates breakthrough vision research through powerful documentaries of discovery, impact, and hope.
Dr. Huang received his undergraduate degree from the Johns Hopkins University, his medical degree in 1990 from the Albert Einstein College of Medicine, and his MBA in 2004 from the Weatherhead School of Management, Case Western Reserve University. He completed his ophthalmology residency training at the Wilmer Ophthalmological Institute at Johns Hopkins University and a fellowship in vitreoretinal diseases and surgery from the Bascom Palmer Eye Institute at the University of Miami.
Francesco Bandello is Full Professor and Chairman at the Department of Ophthalmology at University Vita-Salute, Scientific Institute San Raffaele, Milan, Italy. He is Academic Dean of “Corso di Laurea Specialistica/Magistrale in Medicina e Chirurgia” at the same University. He is also the President of EURETINA, President of Academia Ophthalmologica Europea and Vice-President of EuroLam.
Prof. Bandello is Co-Editor of the European Journal of Ophthalmology and former board member of the Club Jules Gonin and Macula Society. He is member of Executive Board of ESASO Foundation (European School for Advanced Studies in Ophthalmology), member of the Academia Ophthalmologica Internationalis and the Accademia Nazionale di Medicina. Prof. Bandello is co-author of 9 books and he serves as a peer reviewer for grant applications for the NEI. He has authored or co-authored 282 articles and he served as trained Principal Investigator in several clinical trials performed following ICH/GCP and mainly concerning retinal diseases.
Prof Bird retired from full time clinical practice in 2005, to focus on research and teaching. A well-known retinal expert around the world, Prof Bird started his career at the Institute of Ophthalmology as a Lecturer in 1969, after residency training in Ophthalmology at the Moorfields Eye Hospital, Senior Registrar at The London Hospital and The Hospital for Nervous Diseases, Queen Square, followed by a Fellowship in neuro-ophthalmology at Bascom Palmer Eye Institute with Dr. Lawton Smith and a brief period with Dr Hoyt in San Francisco. Subsequently, Prof Bird was appointed as Senior Lecturer, Reader and Professor, and Consultant at Moorfields Eye Hospital. He changed his main interests from neuro-ophthalmology to retina, following which a specialized clinical service was established at the hospital. Over the years, a productive multidisciplinary research team and investigative capabilities developed for investigation of monogenic retinal disorders and age-related macular disease. Investigative techniques included molecular genetics, electrophysiology, psychophysics, specialised imaging and morphology. In order to contribute fully to research, he spent a sabbatical period with Dr Dean Bok at UCLA in 1985.
Dr. José-Alain Sahel is the chair of the Department of Ophthalmology at the University of Pittsburgh School of Medicine, director of the UPMC Eye Center, and the Eye and Ear Foundation Chair of Ophthalmology. He is the founder and director of the Vision Institute in Paris and currently a professor at the Sorbonne’s medical school Université Pierre-et-Marie-Curie. He also holds the positions of Cumberlege Professor of Biomedical Sciences at the Institute of Ophthalmology, University College London, and chairman of the Departments of Ophthalmology at the Quinze-Vingts National Eye Hospital and at the Rothschild Ophthalmology Foundation, both in Paris.
Dr. Sahel studied medicine at Strasbourg University and in Lariboisière, Saint-Louis. He received his medical degree with a Medal of the Faculty of Paris and obtained his specialty certification in ophthalmology. He completed a residency in neurology and neurosurgery at the Louis Pasteur University Hospital in Strasbourg. He also was a research fellow at the Massachusetts Eye and Ear Infirmary and a visiting scholar in the Department of Molecular and Cellular Biology at Harvard University.
Dr. Sahel is known worldwide for his expertise in vision restoration techniques in areas such as stem cell implantation, gene therapy, innovative pharmacologic approaches, and the artificial retina. He is a co-inventor on more than 40 patents, several of which have led to start-up companies including Fovéa Inc., which Dr. Sahel founded and later became the Ophthalmologic Division of Sanofi Aventis. He also is a scientific co-founder of GenSight Biologics Inc. and Pixium Vision Inc. He is a member of 11 editorial boards, including the Journal of Clinical Investigation and Science Translational Medicine.
Dr. Sahel has been the recipient of numerous honors and awards, which include membership in the Legion of Honour (2008), the National Order of Merit (2002), and induction into the Collège de France, the highest honor awarded to a French scientist. He is an elected member of the Académie des sciences-Institut de France, the Académie des technologies, the Academia Ophthalmologia Internationalis, and the German National Academy of Sciences. He has also received the Grand Prix for Neurosciences of the Foundation NRJ, Institut de France; the CNRS Medal of Innovation; the Foundation for Fighting Blindness Trustee Award; and the Liura Liggett-Gund Award, among others. Dr. Sahel holds an honorary degree from the University of Geneva.
Dr. Susan Orr is the Chief Medical Officer and Vice President Medical Affairs of Notal Vision. Following ten years in private optometric practice in Canada, Susan has since held a range of leadership roles at Alcon (a Novartis company) and Janssen (Pharmaceutical company of J&J) before joining Notal Vision in 2016. With a back of the eye focus over the past 15 years, Susan has had both R&D and Commercial responsibilities including Pharmaceutical Alliances (BD&L), Pipeline Strategy, New Product Strategy, Medical Affairs, and Clinical Development programs.
Susan completed both her undergraduate (BSc) and graduate degrees (OD) at the University of Waterloo, Ontario and is currently pursuing an MBA.
Dr. Orr is currently on the advisory board of OWL (Ophthalmic Women Leaders) as well as Chair of the Ophthalmic Industry Professionals (OIP) within OWL.
Adrienne L. Graves, Ph.D. is a visual scientist by training and a global industry leader in ophthalmology. Dr. Graves is the former President and CEO of Santen Inc, and was named the first woman and first non-Japanese global corporate officer of Santen Ltd. Prior to her 15 years at Santen, Dr. Graves spent nine years with Alcon, beginning as a Senior Scientist and progressing through various roles, including Director of International Ophthalmology.
Dr. Graves currently serves as an Independent Director on the following corporate boards: Akorn, Inc., TearLab, Nicox, Envisia Therapeutics, Aerpio Therapeutics, and Encore Vision. She is also a Director on the following Foundation Boards: American Society of Cataract and Refractive Surgery (ASCRS) Foundation, Glaucoma Research Foundation, American Academy of Ophthalmology (AAO) Foundation (Emeritus), Himalayan Cataract Project, and KeepYourSight Foundation.
Dr. Graves co-founded Glaucoma 360 and Ophthalmic Women Leaders (OWL). She received her undergraduate degree from Brown University, her PhD from the University of Michigan, and she completed a postdoctoral fellowship in visual neuroscience at the University of Paris (France).
Ram Palanki, Pharm.D., currently serves as the Senior Vice President of Commercial Strategy and Operations at REGENXBIO.
Dr. Palanki brings more than 15 years of experience in ophthalmology across pharmaceutical strategy and development, marketing, market access, sales, pricing, reimbursement, supply chain, distribution, business development, medical affairs and portfolio planning leadership.
Prior to joining REGENXBIO, he was Senior Vice President of Commercial for all of Americas at Santen Inc. Preceding Santen, he was Global Head of Marketing and Sales at Thrombogenics, Inc. where he led the commercial launch for Jetrea, a novel proteolytic enzyme therapy for symptomatic vitreomacular adhesion. Previously, Dr. Palanki served as Director of Global Marketing and Sales at NeoVista, Inc. and earlier in his career, held several positions at Genentech as part of the team that developed and launched Lucentis. Prior to Genentech, he worked at Eyetech Pharmaceuticals as part of the initial team submitting the New Drug Application for Macugen and at Novartis Pharmaceuticals in the New Product Commercialization group.
Dr. Palanki earned his Pharm.D. at Albany College of Pharmacy in New York and completed his postdoctoral fellowship at Rutgers University in New Jersey.
Pravin U. Dugel, MD graduated Summa Cum Laude from Columbia University in the City of New York. He then attended UCLA School of Medicine, followed by residency in ophthalmology at the USC Eye Institute, Keck School of Medicine. Thereafter, he completed his medical retina fellowship at the Bascom Palmer Eye Institute and his surgical retina fellowship at the USC Eye Institute, where he was elected to serve on the faculty as the Resident Director.
Dr. Dugel joined Retinal Consultants of Arizona in July 1994 and is currently Managing Partner, Retinal Consultants of Arizona; Retinal Research Institute; Clinical Professor, USC Eye Institute, Keck School of Medicine, University of Southern California; Founding Member, Spectra Eye Institute, Sun City; Physician Executive Director, Banner Eye Institute, Banner University Medical Center, University of Arizona.
Dr. Dugel has authored innumerable papers and book chapters and has been invited to lecture at prestigious meetings, Visiting Professorships and Universities worldwide. He is on the Editorial Board of several major-medical journals. Dr. Dugel is internationally recognized as a major clinical researcher and has been a primary investigator in over 100 multicenter clinical trials. He has been elected Subspecialty Day Board Chairman for the American Academy of Ophthalmology, to the Board of Directors of the American Society of Retina Specialists, and to the largest retina society in Europe, EuRetina. He serves on the Scientific Advisory Board of numerous companies, including Aerpio, Alcon, Digisight, Genentech, Novartis, Ophthotech, Opthea, Roche, and TrueVision.
In Arizona, he has served as President of the Phoenix Ophthalmology Society and is on the Board of Directors of the Arizona Ophthalmology Society. Since 1994, Dr. Dugel has been a member of the U.S. Department of Health and Human Services agency, providing eye care services to Native Americans. He has co-founded a scholarship and mentorship program – Project SENA – with his two daughters, creating educational opportunities for Native American youth and adults.
Dr. Dugel is Chairman of the ORBIS (“Flying Eye Hospital”) International Medical Advisory Board and the Medical Strategic Committee. With ORBIS, he travels to developing countries to teach surgical techniques to local ophthalmologists and provide free surgery for those suffering from preventable blindness.
In 2017, Dr. Dugel was inducted into the “Retina Hall of Fame,” which honors ophthalmologists for their exceptional lifetime achievements and contributions to the field of retina.
Prof. Wong is a senior consultant ophthalmologist sub-specializing in medical retina at the Singapore National Eye Centre (SNEC). He is also the Provost’s Chair of Ophthalmology at Duke-NUS Medical School, National University of Singapore where he is concurrently Vice-Dean, Office of Clinical Sciences.
Prof. Wong is a physician-scientist, practicing as a retinal specialist and with a broad-based research focused on the epidemiology and clinical treatment outcomes of retinal diseases, such as diabetic and hypertensive retinopathy and age-related macular degeneration. He has published more than 1,000 peer-reviewed papers, including papers in the New England Journal of Medicine and the Lancet, has given more than 300 invited named, plenary and symposium lectures. He chairs the International Council of Ophthalmology’s Committee on Diabetic Eye Care, sits on many international professional bodies, and is on Editorial Boards of JAMA Ophthalmology, IOVS, Diabetes Care, and other journals.
Dr. Dimitri Azar is an internationally recognized ophthalmic surgeon who served as Dean of the College of Medicine at University of Illinois from 2011 to 2017. He remain a Distinguished Professor of Ophthalmology at the University, along with being the Senior Director for Ophthalmic Innovations at Verily.
Dr. Azar joined the faculty at University of Illnois in 2006 as Head of the Department of Ophthalmology & Visual Sciences. Previously he was a tenured Professor of Ophthalmology at Harvard Medical School, Director of the Cornea Service at Massachusetts Eye and Ear Infirmary, Senior Scientist at Schepens Eye Institute and a faculty member at Johns Hopkins School of Medicine. He earned an executive MBA from University of Chicago. Dr. Azar is board certified in Ophthalmology.
Dr. Azar was an independent non-Executive Director of Novartis AG between 2012 – 2019. He serves as a Member of Verily Advisory Board at Verily Life Sciences LLC and also on the board of Verb Surgical Inc.
Dr Rajat N Agrawal is an ophthalmologist and a retina specialist, known for his clinical acumen, research work (he is a co-inventor & a co-patent holder of ARGUS-II) and interest in teaching, as well as his social commitment.
Dr Agrawal completed his medical education and residency in Nagpur & Mumbai (formerly Bombay), before heading to join Sankara Nethralaya, Chennai, India, for a retina fellowship. He joined the Institute as a faculty after the completion of the fellowship and worked for seven years, before heading to Hong Kong on an invitation to teach, train and manage/operate complicated cases at the Chinese University of Hong Kong and other hospitals in the city. Later, he was invited to the Commonwealth of the Bahamas, where he was the only Retina Specialist in the country & Director of the Ophthalmology Program at the Princess Margaret Hospital in Nassau, as well as the Residency Director for residents from Yale University Department of Ophthalmology. In 2003, he joined USC/Doheny Eye Institute in Los Angeles, CA, where he was involved, apart from clinical care and teaching, in ideation, research & development of the ARGUS-II, devising the surgical procedure for the implant procedure and the clinical trials that followed in six centers in the US and four in Europe. ARGUS-II is currently the only approved treatment for advanced retinitis pigmentosa in the US and in Europe at this time. Dr Agrawal also has a Masters degree in Regulatory Sciences from USC.
Dr Agrawal is the President & CEO of Retina Global.